1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: CNS Clinical Trials Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. CNS Clinical Trials Market, by Indication
8.1.1. Alzheimer's Disease
8.1.1.1. Market Revenue and Forecast
8.1.2. Parkinson's Disease
8.1.2.1. Market Revenue and Forecast
8.1.3. Epilepsy
8.1.3.1. Market Revenue and Forecast
8.1.4. Multiple Sclerosis
8.1.4.1. Market Revenue and Forecast
8.1.5. Depression
8.1.5.1. Market Revenue and Forecast
8.1.6. Schizophrenia
8.1.6.1. Market Revenue and Forecast
8.1.7. Stroke
8.1.7.1. Market Revenue and Forecast
9.1. CNS Clinical Trials Market, by Phase
9.1.1. Phase I
9.1.1.1. Market Revenue and Forecast
9.1.2. Phase II
9.1.2.1. Market Revenue and Forecast
9.1.3. Phase III
9.1.3.1. Market Revenue and Forecast
9.1.4. Phase IV
9.1.4.1. Market Revenue and Forecast
10.1. CNS Clinical Trials Market, by Study Design
10.1.1. Interventional Studies
10.1.1.1. Market Revenue and Forecast
10.1.2. Observational Studies
10.1.2.1. Market Revenue and Forecast
11.1. CNS Clinical Trials Market, by End User
11.1.1. Pharmaceutical Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Biotechnology Companies
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic and Research Institutes
11.1.3.1. Market Revenue and Forecast
12.1. CNS Clinical Trials Market, by Trial Type
12.1.1. Drug Trials
12.1.1.1. Market Revenue and Forecast
12.1.2. Biologics Trials
12.1.2.1. Market Revenue and Forecast
12.1.3. Gene and Cell Therapy Trials
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Indication
13.1.2. Market Revenue and Forecast, by Phase
13.1.3. Market Revenue and Forecast, by Study Design
13.1.4. Market Revenue and Forecast, by End User
13.1.5. Market Revenue and Forecast, by Trial Type
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Indication
13.1.6.2. Market Revenue and Forecast, by Phase
13.1.6.3. Market Revenue and Forecast, by Study Design
13.1.6.4. Market Revenue and Forecast, by End User
13.1.6.5. Market Revenue and Forecast, by Trial Type
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Indication
13.1.7.2. Market Revenue and Forecast, by Phase
13.1.7.3. Market Revenue and Forecast, by Study Design
13.1.7.4. Market Revenue and Forecast, by End User
13.1.7.5. Market Revenue and Forecast, by Trial Type
13.2. Europe
13.2.1. Market Revenue and Forecast, by Indication
13.2.2. Market Revenue and Forecast, by Phase
13.2.3. Market Revenue and Forecast, by Study Design
13.2.4. Market Revenue and Forecast, by End User
13.2.5. Market Revenue and Forecast, by Trial Type
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Indication
13.2.6.2. Market Revenue and Forecast, by Phase
13.2.6.3. Market Revenue and Forecast, by Study Design
13.2.7. Market Revenue and Forecast, by End User
13.2.8. Market Revenue and Forecast, by Trial Type
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Indication
13.2.9.2. Market Revenue and Forecast, by Phase
13.2.9.3. Market Revenue and Forecast, by Study Design
13.2.10. Market Revenue and Forecast, by End User
13.2.11. Market Revenue and Forecast, by Trial Type
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Indication
13.2.12.2. Market Revenue and Forecast, by Phase
13.2.12.3. Market Revenue and Forecast, by Study Design
13.2.12.4. Market Revenue and Forecast, by End User
13.2.13. Market Revenue and Forecast, by Trial Type
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Indication
13.2.14.2. Market Revenue and Forecast, by Phase
13.2.14.3. Market Revenue and Forecast, by Study Design
13.2.14.4. Market Revenue and Forecast, by End User
13.2.15. Market Revenue and Forecast, by Trial Type
13.3. APAC
13.3.1. Market Revenue and Forecast, by Indication
13.3.2. Market Revenue and Forecast, by Phase
13.3.3. Market Revenue and Forecast, by Study Design
13.3.4. Market Revenue and Forecast, by End User
13.3.5. Market Revenue and Forecast, by Trial Type
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Indication
13.3.6.2. Market Revenue and Forecast, by Phase
13.3.6.3. Market Revenue and Forecast, by Study Design
13.3.6.4. Market Revenue and Forecast, by End User
13.3.7. Market Revenue and Forecast, by Trial Type
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Indication
13.3.8.2. Market Revenue and Forecast, by Phase
13.3.8.3. Market Revenue and Forecast, by Study Design
13.3.8.4. Market Revenue and Forecast, by End User
13.3.9. Market Revenue and Forecast, by Trial Type
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Indication
13.3.10.2. Market Revenue and Forecast, by Phase
13.3.10.3. Market Revenue and Forecast, by Study Design
13.3.10.4. Market Revenue and Forecast, by End User
13.3.10.5. Market Revenue and Forecast, by Trial Type
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Indication
13.3.11.2. Market Revenue and Forecast, by Phase
13.3.11.3. Market Revenue and Forecast, by Study Design
13.3.11.4. Market Revenue and Forecast, by End User
13.3.11.5. Market Revenue and Forecast, by Trial Type
13.4. MEA
13.4.1. Market Revenue and Forecast, by Indication
13.4.2. Market Revenue and Forecast, by Phase
13.4.3. Market Revenue and Forecast, by Study Design
13.4.4. Market Revenue and Forecast, by End User
13.4.5. Market Revenue and Forecast, by Trial Type
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Indication
13.4.6.2. Market Revenue and Forecast, by Phase
13.4.6.3. Market Revenue and Forecast, by Study Design
13.4.6.4. Market Revenue and Forecast, by End User
13.4.7. Market Revenue and Forecast, by Trial Type
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Indication
13.4.8.2. Market Revenue and Forecast, by Phase
13.4.8.3. Market Revenue and Forecast, by Study Design
13.4.8.4. Market Revenue and Forecast, by End User
13.4.9. Market Revenue and Forecast, by Trial Type
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Indication
13.4.10.2. Market Revenue and Forecast, by Phase
13.4.10.3. Market Revenue and Forecast, by Study Design
13.4.10.4. Market Revenue and Forecast, by End User
13.4.10.5. Market Revenue and Forecast, by Trial Type
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Indication
13.4.11.2. Market Revenue and Forecast, by Phase
13.4.11.3. Market Revenue and Forecast, by Study Design
13.4.11.4. Market Revenue and Forecast, by End User
13.4.11.5. Market Revenue and Forecast, by Trial Type
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Indication
13.5.2. Market Revenue and Forecast, by Phase
13.5.3. Market Revenue and Forecast, by Study Design
13.5.4. Market Revenue and Forecast, by End User
13.5.5. Market Revenue and Forecast, by Trial Type
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Indication
13.5.6.2. Market Revenue and Forecast, by Phase
13.5.6.3. Market Revenue and Forecast, by Study Design
13.5.6.4. Market Revenue and Forecast, by End User
13.5.7. Market Revenue and Forecast, by Trial Type
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Indication
13.5.8.2. Market Revenue and Forecast, by Phase
13.5.8.3. Market Revenue and Forecast, by Study Design
13.5.8.4. Market Revenue and Forecast, by End User
13.5.8.5. Market Revenue and Forecast, by Trial Type
14.1. IQVIA
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. ICON plc
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Labcorp Drug Development
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Syneos Health
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Parexel
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Medpace
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. PPD
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Worldwide Clinical Trials
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. PSI CRO
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Premier Research
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
